FiercePharma

New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira®

ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Patients with active moderate to severe rheumatoid arthritis (RA) inadequately responding to either etanercept (Enbrel ®) or adalimumab (Humira ®) and who were ...
Healio

Safety profile of Remsima biosimilar appears to be similar to Remicade in patients with RA, AS

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A safety profile consistent with that of ...
Healio

SB2 biosimilar to Remicade shows comparable response, safety profile in patients with RA

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Patients with rheumatoid arthritis showed ...
Medscape

FDA Approvals: Advate and Remicade

June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...
MM&M

Therapeutic Focus 2010: Rheumatology

TherapeuticFocus:Rheumatology.pdfSeveral factors are driving greater market-share estimates of products to treat rheumatoid arthritis (RA) and other conditions like ankylosing spondylitis, Crohn’s ...
EurekAlert!

Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...
Medscape

International Approvals: Lyrica and Remicade

October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...
MM&M

With RA indication, J&J’s Simponi an up-and-comer

Johnson & Johnson’s biotech arm, Janssen Biotech, received an expanded indication for its anti-TNF (tumor necrosis factor) infusion therapy, Simponi Aria (golimumab), for patients with ...
FiercePharma

Hospira's Inflectra (infliximab) the first biosimilar monoclonal antibody to be approved in Europe

LEAMINGTON SPA, England, Sept. 10, 2013 /PRNewswire/ -- Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) ...
EurekAlert!

FDA grants priority review of Remicade® for children with Crohn's disease

HORSHAM, Pa. - Centocor, Inc. announced today that the supplemental Biologics License Application (sBLA) for REMICADE (R) (infliximab) for the treatment of pediatric Crohn's disease has been accepted ...
Los Angeles Times

Panel OKs Amgen Arthritis Medicine

Amgen Inc. moved closer to entering the $6.9-billion market for rheumatoid arthritis drugs Thursday as a regulatory panel recommended approval of its experimental treatment Kineret. The drug, which ...